Drug intelligence / Profile preview

ANJ114

Development stage: Unknown
Lead developer: Anji Pharma
Modality: Small Molecules

Overview

**ANJ114** is a small molecule inhibitor of HCK (hematopoietic cell kinase), a protein kinase that serves as a key survival mechanism for leukemic stem cells. Developed by Anji Pharmaceuticals, it targets oncology indications, particularly leukemia, by blocking HCK function to disrupt cancer cell survival and tumor formation. As an early-stage asset, it is part of Anji's oncology pipeline aimed at advancing into clinical trials.

Targets

HCK (Haematopoietic Cell Kinase)

Beyond the preview

Go deeper on ANJ114.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANJ114.

Explore the full profile